Differentiation	O
of	O
U-937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
of	O
two	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O

One	O
hour	O
pulse-treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	B-protein
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse-treatment	O
with	O
6	O
microM	O
ICRF-193	O
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane-bound	B-protein
enzyme	I-protein
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane-bound	B-protein
and	I-protein
cytosolic	I-protein
enzyme	I-protein
.	O

By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

When	O
used	O
at	O
differentiation-inducing	O
concentrations	O
,	O
both	O
topoisomerase	B-protein
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	B-protein
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide-treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	B-cell_type
cells	I-cell_type
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF-kappa	B-protein
(	I-protein
B	I-protein
)	I-protein
and	O
EGR-1	B-protein
transcription	B-protein
factors	I-protein
was	O
little	O
affected	O
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-	O
topoisomerase	B-protein
drugs	O
.	O

Journal	NULL
of	NULL
Cell	NULL
Science	NULL
110	NULL
,	NULL
337-343	NULL
(	NULL
1997	NULL
)	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
©	NULL
The	NULL
Company	NULL
of	NULL
Biologists	NULL
Limited	NULL
1997	NULL
JCS9518	NULL
337	NULL
Differentiation	NULL
of	NULL
U-937	NULL
promonocytic	NULL
cells	NULL
by	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
,	NULL
two	NULL
antitumour	NULL
DNA	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
with	NULL
different	NULL
mechanisms	NULL
of	NULL
action	NULL
Concepcion	NULL
Pérez	NULL
,	NULL
Nuria	NULL
E.	NULL
Vilaboa	NULL
'	NULL
,	NULL
Laura	NULL
Garcia-Bermejo'~	NULL
,	NULL
Elena	NULL
de	NULL
Blas	NULL
'	NULL
,	NULL
Andrew	NULL
M.	NULL
Creighton	NULL
``	NULL
and	NULL
Patricio	NULL
Aller'*	NULL
1Centro	NULL
de	NULL
Investigaciones	NULL
Biolégicas	NULL
,	NULL
CSIC	NULL
,	NULL
Velazquez	NULL
144	NULL
,	NULL
28006-Madrid	NULL
,	NULL
Spain	NULL
Instituto	NULL
de	NULL
Quimica	NULL
Médica	NULL
,	NULL
CSIC	NULL
,	NULL
Juan	NULL
de	NULL
la	NULL
Cierva	NULL
3	NULL
,	NULL
28006-Madrid	NULL
,	NULL
Spain	NULL
Departamento	NULL
de	NULL
Biologia	NULL
Celular	NULL
y	NULL
Genética	NULL
,	NULL
Universidad	NULL
de	NULL
Alcala	NULL
,	NULL
Madrid	NULL
,	NULL
Spain	NULL
4Department	NULL
of	NULL
Reproductive	NULL
Physiology	NULL
,	NULL
St	NULL
Bartholomew	NULL
's	NULL
Hospital	NULL
,	NULL
London	NULL
EC1A	NULL
7BE	NULL
,	NULL
UK	NULL
*Author	NULL
for	NULL
correspondence	NULL
SUMMARY	NULL
We	NULL
have	NULL
compared	NULL
the	NULL
action	NULL
on	NULL
U-937	NULL
human	NULL
promonocytic	NULL
leukemia	NULL
cells	NULL
of	NULL
two	NULL
DNA	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
,	NULL
namely	NULL
the	NULL
epipodophyllotoxin	NULL
etoposide	NULL
and	NULL
the	NULL
bisdioxopiperazine	NULL
ICRF-193	NULL
.	NULL

One	NULL
hour	NULL
pulse-treatment	NULL
with	NULL
3	NULL
uM	NULL
etoposide	NULL
caused	NULL
topoisomerase-asso-ciated	NULL
,	NULL
primary	NULL
DNA	NULL
breakage	NULL
,	NULL
which	NULL
was	NULL
rapidly	NULL
followed	NULL
by	NULL
apoptosis	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
these	NULL
effects	NULL
were	NULL
not	NULL
observed	NULL
upon	NULL
pulse-treatment	NULL
with	NULL
6	NULL
uM	NULL
ICRF-193	NULL
.	NULL

However	NULL
,	NULL
continuous	NULL
treatments	NULL
with	NULL
subcytotoxic	NULL
concentrations	NULL
of	NULL
etoposide	NULL
(	NULL
0.15	NULL
uM	NULL
)	NULL
and	NULL
ICRF-193	NULL
(	NULL
0.3	NULL
uM	NULL
)	NULL
produced	NULL
several	NULL
similar	NULL
effects	NULL
,	NULL
namely	NULL
decreased	NULL
cell	NULL
proliferation	NULL
,	NULL
accumulation	NULL
of	NULL
cells	NULL
at	NULL
G3	NULL
,	NULL
increase	NULL
in	NULL
cell	NULL
mass	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
differentiation	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
etoposide	NULL
produced	NULL
a	NULL
biphasic	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
which	NULL
consisted	NULL
in	NULL
an	NULL
early	NULL
transient	NULL
activation	NULL
(	NULL
from	NULL
hours	NULL
1	NULL
to	NULL
6	NULL
)	NULL
of	NULL
the	NULL
membrane-bound	NULL
enzyme	NULL
followed	NULL
by	NULL
a	NULL
later	NULL
activation	NULL
(	NULL
hour	NULL
48	NULL
)	NULL
of	NULL
the	NULL
total	NULL
,	NULL
membrane-bound	NULL
and	NULL
cytosolic	NULL
enzyme	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
ICRF-193	NULL
only	NULL
provoked	NULL
a	NULL
late	NULL
activation	NULL
(	NULL
from	NULL
hours	NULL
72	NULL
to	NULL
96	NULL
)	NULL
of	NULL
the	NULL
total	NULL
enzyme	NULL
.	NULL

When	NULL
used	NULL
at	NULL
differentiation-inducing	NULL
concentrations	NULL
,	NULL
both	NULL
topoisomerase	NULL
inhibitors	NULL
caused	NULL
a	NULL
great	NULL
stimulation	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
,	NULL
with	NULL
maximum	NULL
value	NULL
at	NULL
hour	NULL
12	NULL
in	NULL
etoposide-treated	NULL
cells	NULL
and	NULL
at	NULL
hour	NULL
48	NULL
in	NULL
ICRF-193-treated	NULL
cells	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
EGR-1	NULL
transcription	NULL
factors	NULL
was	NULL
little	NULL
affected	NULL
.	NULL

It	NULL
is	NULL
concluded	NULL
that	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
may	NULL
induce	NULL
the	NULL
differentiation	NULL
of	NULL
promonocytic	NULL
cells	NULL
,	NULL
independently	NULL
of	NULL
their	NULL
capacity	NULL
to	NULL
cause	NULL
DNA	NULL
strand	NULL
breaks	NULL
.	NULL

However	NULL
,	NULL
there	NULL
are	NULL
other	NULL
effects	NULL
,	NULL
such	NULL
as	NULL
the	NULL
early	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
which	NULL
are	NULL
probably	NULL
derived	NULL
from	NULL
the	NULL
production	NULL
of	NULL
primary	NULL
DNA	NULL
breakage	NULL
by	NULL
some	NULL
anti-topoisomerase	NULL
drugs	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
Etoposide	NULL
,	NULL
ICRF-193	NULL
,	NULL
Topoisomerase	NULL
II	NULL
inhibition	NULL
,	NULL
Differentiation	NULL
,	NULL
Apoptosis	NULL
,	NULL
U-937	NULL
cell	NULL
INTRODUCTION	NULL
DNA	NULL
topoisomerases	NULL
are	NULL
enzymes	NULL
capable	NULL
of	NULL
generating	NULL
local	NULL
changes	NULL
in	NULL
DNA	NULL
topology	NULL
which	NULL
are	NULL
required	NULL
for	NULL
DNA	NULL
repli-cation	NULL
,	NULL
transcription	NULL
,	NULL
recombination	NULL
and	NULL
chromatid	NULL
segregation	NULL
(	NULL
Vosberg	NULL
,	NULL
1985	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
enzymes	NULL
are	NULL
targets	NULL
for	NULL
an	NULL
important	NULL
number	NULL
of	NULL
antitumour	NULL
drugs	NULL
.	NULL

This	NULL
is	NULL
the	NULL
case	NULL
for	NULL
DNA	NULL
intercalating	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
amsacrine	NULL
,	NULL
doxorubicin	NULL
and	NULL
mitoxantrone	NULL
,	NULL
and	NULL
of	NULL
non	NULL
intercalators	NULL
,	NULL
such	NULL
as	NULL
the	NULL
epipodophyllotoxins	NULL
etoposide	NULL
(	NULL
VP-16	NULL
)	NULL
and	NULL
teniposide	NULL
(	NULL
VM-26	NULL
)	NULL
.	NULL

These	NULL
agents	NULL
cause	NULL
the	NULL
stabilization	NULL
of	NULL
the	NULL
cleavable	NULL
DNA-topoisomerase	NULL
II	NULL
covalent	NULL
complexes	NULL
,	NULL
preventing	NULL
subsequent	NULL
DNA	NULL
religation	NULL
and	NULL
producing	NULL
'primary	NULL
'	NULL
,	NULL
topoisomerase-asso-ciated	NULL
DNA	NULL
strand	NULL
breaks	NULL
(	NULL
D'Arpa	NULL
and	NULL
Liu	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

When	NULL
the	NULL
drugs	NULL
are	NULL
applied	NULL
at	NULL
high	NULL
concentrations	NULL
,	NULL
the	NULL
primary	NULL
DNA	NULL
breakage	NULL
may	NULL
be	NULL
rapidly	NULL
followed	NULL
by	NULL
'secondary	NULL
'	NULL
,	NULL
nucleosome-sized	NULL
DNA	NULL
fragmentation	NULL
,	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
(	NULL
Bertrand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
anti-topoisomerase	NULL
drugs	NULL
may	NULL
also	NULL
induce	NULL
differentiation	NULL
when	NULL
applied	NULL
at	NULL
subcytotoxic	NULL
concentrations	NULL
.	NULL

This	NULL
has	NULL
been	NULL
mainly	NULL
demonstrated	NULL
in	NULL
myeloid	NULL
and	NULL
erythroid	NULL
cells	NULL
(	NULL
Rappa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Rius	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Constantinou	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
but	NULL
also	NULL
in	NULL
other	NULL
systems	NULL
such	NULL
as	NULL
mouse	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
(	NULL
Kondo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
neuroblastoma	NULL
cells	NULL
(	NULL
Larcher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
problems	NULL
derived	NULL
from	NULL
the	NULL
use	NULL
of	NULL
'classical	NULL
'	NULL
topoisomerase	NULL
inhibitors	NULL
is	NULL
that	NULL
,	NULL
because	NULL
of	NULL
the	NULL
inevitable	NULL
production	NULL
of	NULL
DNA	NULL
breakage	NULL
,	NULL
it	NULL
is	NULL
impossible	NULL
to	NULL
know	NULL
whether	NULL
the	NULL
observed	NULL
effects	NULL
are	NULL
due	NULL
to	NULL
topoisomerase	NULL
inhibition	NULL
itself	NULL
or	NULL
to	NULL
the	NULL
drug-generated	NULL
DNA	NULL
damage	NULL
.	NULL

Actually	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
DNA-damaging	NULL
agents	NULL
which	NULL
do	NULL
not	NULL
inhibit	NULL
topoisomerase	NULL
activity	NULL
,	NULL
such	NULL
as	NULL
X-radiation	NULL
,	NULL
cytarabine	NULL
and	NULL
alkylating	NULL
agents	NULL
,	NULL
may	NULL
induce	NULL
differentiation	NULL
in	NULL
several	NULL
cell	NULL
systems	NULL
(	NULL
Wangenheim	NULL
and	NULL
Howard	NULL
,	NULL
1978	NULL
;	NULL
Mata	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Ballester	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

To	NULL
shed	NULL
light	NULL
on	NULL
this	NULL
problem	NULL
,	NULL
we	NULL
have	NULL
compared	NULL
the	NULL
action	NULL
of	NULL
etoposide	NULL
and	NULL
the	NULL
bisdioxopiperazine	NULL
ICRF-193	NULL
.	NULL

ICRF-193	NULL
338	NULL
-	NULL
C.	NULL
Pérez	NULL
and	NULL
others	NULL
and	NULL
related	NULL
compounds	NULL
represent	NULL
a	NULL
novel	NULL
class	NULL
of	NULL
DNA	NULL
topoisomerase	NULL
inhibitors	NULL
with	NULL
antitumour	NULL
activity	NULL
which	NULL
do	NULL
not	NULL
stabilize	NULL
the	NULL
cleavable	NULL
complex	NULL
(	NULL
Tanabe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Instead	NULL
,	NULL
they	NULL
stabilize	NULL
the	NULL
enzyme	NULL
in	NULL
the	NULL
form	NULL
of	NULL
a	NULL
closed	NULL
protein	NULL
clamp	NULL
(	NULL
Roca	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
in	NULL
such	NULL
a	NULL
manner	NULL
that	NULL
the	NULL
cells	NULL
do	NULL
not	NULL
accumulate	NULL
DNA	NULL
breakage	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
in	NULL
spite	NULL
of	NULL
their	NULL
different	NULL
mechanisms	NULL
of	NULL
action	NULL
,	NULL
both	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
induce	NULL
the	NULL
differentiation	NULL
of	NULL
U-937	NULL
human	NULL
promonocytic	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
and	NULL
drug	NULL
treatments	NULL
The	NULL
U-937	NULL
cells	NULL
(	NULL
Sundstrom	NULL
and	NULL
Nilsson	NULL
,	NULL
1976	NULL
)	NULL
used	NULL
were	NULL
mycoplasma-free	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Gibco	NULL
BRL	NULL
:	NULL
Life	NULL
Technologies	NULL
,	NULL
Paisley	NULL
,	NULL
UK	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inacti-vated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Gibco	NULL
BRL	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
Hepes	NULL
buffer	NULL
,	NULL
and	NULL
0.2	NULL
%	NULL
sodium	NULL
bicarbonate	NULL
in	NULL
a	NULL
humidified	NULL
5	NULL
%	NULL
CO2	NULL
atmosphere	NULL
at	NULL
37°C	NULL
.	NULL

12-O-tetradecanoylphorbol-13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
and	NULL
etoposide	NULL
,	NULL
obtained	NULL
from	NULL
Sigma	NULL
Quimica	NULL
,	NULL
Madrid	NULL
,	NULL
Spain	NULL
,	NULL
were	NULL
dissolved	NULL
in	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
at	NULL
1.5	NULL
and	NULL
20	NULL
mM	NULL
,	NULL
respectively	NULL
.	NULL

ICRF-193	NULL
,	NULL
synthesized	NULL
in	NULL
one	NULL
of	NULL
our	NULL
laboratories	NULL
(	NULL
St	NULL
Bartholomew	NULL
's	NULL
Hospital	NULL
,	NULL
London	NULL
,	NULL
UK	NULL
)	NULL
,	NULL
was	NULL
dissolved	NULL
at	NULL
10	NULL
mM	NULL
in	NULL
DMSO	NULL
.	NULL

The	NULL
solutions	NULL
were	NULL
stored	NULL
at	NULL
-20°C	NULL
.	NULL

At	NULL
the	NULL
final	NULL
concentrations	NULL
used	NULL
,	NULL
the	NULL
solvent	NULL
was	NULL
without	NULL
significant	NULL
effects	NULL
on	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Cells	NULL
were	NULL
seeded	NULL
for	NULL
experiments	NULL
in	NULL
a	NULL
mixture	NULL
of	NULL
old	NULL
and	NULL
fresh	NULL
media	NULL
(	NULL
1:3	NULL
,	NULL
v/v	NULL
)	NULL
at	NULL
10°	NULL
cells/ml	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
the	NULL
doubling	NULL
time	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
untreated	NULL
cultures	NULL
was	NULL
approximately	NULL
18	NULL
hours	NULL
.	NULL

Cells	NULL
from	NULL
control	NULL
cultures	NULL
were	NULL
harvested	NULL
at	NULL
the	NULL
exponential	NULL
growth	NULL
phase	NULL
.	NULL

Cells	NULL
from	NULL
treated	NULL
cultures	NULL
were	NULL
harvested	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
in	NULL
each	NULL
experiment	NULL
.	NULL

To	NULL
prevent	NULL
long-term	NULL
cultures	NULL
from	NULL
reaching	NULL
plateau	NULL
densities	NULL
or	NULL
nutrient	NULL
exhaustion	NULL
,	NULL
at	NULL
the	NULL
second	NULL
day	NULL
of	NULL
treatment	NULL
(	NULL
approximately	NULL
6-7	NULL
%	NULL
10°	NULL
cells/ml	NULL
in	NULL
untreated	NULL
cultures	NULL
)	NULL
they	NULL
were	NULL
supplemented	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
fresh	NULL
medium	NULL
containing	NULL
the	NULL
corresponding	NULL
drug	NULL
.	NULL

Cell	NULL
growth	NULL
and	NULL
viability	NULL
were	NULL
checked	NULL
using	NULL
a	NULL
hemocytometer	NULL
and	NULL
trypan	NULL
blue	NULL
exclusion	NULL
,	NULL
respectively	NULL
.	NULL

Alkaline	NULL
elution	NULL
assays	NULL
Cells	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
hours	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.1	NULL
uCi/ml	NULL
of	NULL
methyl	NULL
[	NULL
»	NULL
HIJthymidine	NULL
(	NULL
2	NULL
Ci/mmol	NULL
,	NULL
Amersham	NULL
Iberica	NULL
,	NULL
Madrid	NULL
,	NULL
Spain	NULL
)	NULL
plus	NULL
1	NULL
uM	NULL
of	NULL
unlabeled	NULL
thymidine	NULL
,	NULL
after	NULL
which	NULL
they	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
allowed	NULL
to	NULL
recover	NULL
in	NULL
RPMI	NULL
medium	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
precursor	NULL
.	NULL

Following	NULL
drug	NULL
treatment	NULL
or	NULL
irra-diation	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
total	NULL
(	NULL
single	NULL
plus	NULL
double	NULL
)	NULL
DNA	NULL
breaks	NULL
was	NULL
estimated	NULL
by	NULL
DNA-denaturing	NULL
alkaline	NULL
solution	NULL
(	NULL
pH	NULL
12.1	NULL
)	NULL
following	NULL
the	NULL
method	NULL
of	NULL
Kohn	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
apoptosis	NULL
Determination	NULL
of	NULL
DNA	NULL
degradation	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Rubin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

To	NULL
analyze	NULL
changes	NULL
in	NULL
nuclear	NULL
structure	NULL
,	NULL
5x10°	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
50	NULL
pul	NULL
PBS	NULL
and	NULL
mounted	NULL
on	NULL
glass	NULL
slides	NULL
.	NULL

After	NULL
fixation	NULL
for	NULL
20	NULL
minutes	NULL
in	NULL
cold	NULL
absolute	NULL
methanol	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stained	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
4,6-diamidino-2-phenylindole	NULL
(	NULL
DAPI	NULL
,	NULL
at	NULL
1	NULL
ug/ml	NULL
in	NULL
phosphate	NULL
buffered	NULL
saline	NULL
,	NULL
PBS	NULL
)	NULL
,	NULL
and	NULL
examined	NULL
by	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Determination	NULL
of	NULL
DNA	NULL
content	NULL
and	NULL
cell	NULL
mass	NULL
Simultaneous	NULL
measurement	NULL
of	NULL
DNA	NULL
content	NULL
(	NULL
as	NULL
a	NULL
determination	NULL
of	NULL
cell	NULL
cycle	NULL
distribution	NULL
)	NULL
and	NULL
total	NULL
protein	NULL
content	NULL
(	NULL
as	NULL
an	NULL
estimation	NULL
of	NULL
cell	NULL
mass	NULL
)	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
double	NULL
staining	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
propidium	NULL
iodide	NULL
and	NULL
fluorescein	NULL
isothiocyanate	NULL
,	NULL
followed	NULL
by	NULL
their	NULL
analysis	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
as	NULL
earlier	NULL
described	NULL
(	NULL
Aller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
differentiation	NULL
markers	NULL
To	NULL
determine	NULL
nitro	NULL
blue	NULL
tetrazolium	NULL
(	NULL
NBT	NULL
)	NULL
reduction	NULL
,	NULL
106	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
37°C	NULL
in	NULL
1	NULL
ml	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
NBT	NULL
and	NULL
150	NULL
nM	NULL
TPA	NULL
,	NULL
after	NULL
which	NULL
0.2	NULL
ml	NULL
of	NULL
5	NULL
N	NULL
HCI	NULL
was	NULL
added	NULL
and	NULL
the	NULL
cells	NULL
left	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Upon	NULL
centrifugation	NULL
,	NULL
the	NULL
formazan	NULL
precipitates	NULL
were	NULL
dissolved	NULL
in	NULL
0.5	NULL
ml	NULL
DMSO	NULL
and	NULL
the	NULL
absorbance	NULL
measured	NULL
by	NULL
spectrometry	NULL
at	NULL
560	NULL
nm	NULL
.	NULL

The	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
CR3	NULL
(	NULL
CD11b/CD18	NULL
)	NULL
and	NULL
p150,95	NULL
(	NULL
CD11c/CD18	NULL
)	NULL
leukocyte	NULL
integrins	NULL
was	NULL
determined	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
combined	NULL
with	NULL
flow	NULL
cytometry	NULL
,	NULL
and	NULL
the	NULL
intracellular	NULL
accumulation	NULL
of	NULL
the	NULL
intermediate	NULL
filament	NULL
protein	NULL
vimentin	NULL
measured	NULL
by	NULL
immunoblot	NULL
assays	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Mata	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
assays	NULL
Cells	NULL
(	NULL
5x10°	NULL
)	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
suspended	NULL
in	NULL
0.4	NULL
ml	NULL
of	NULL
ice-cold	NULL
extraction	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
containing	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
EGTA	NULL
,	NULL
25	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
25	NULL
pg/ml	NULL
leupeptin	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
disrupted	NULL
with	NULL
a	NULL
Dounce	NULL
homogenizer	NULL
,	NULL
after	NULL
which	NULL
the	NULL
homogenates	NULL
were	NULL
first	NULL
centrifuged	NULL
for	NULL
2	NULL
minutes	NULL
in	NULL
a	NULL
microfuge	NULL
to	NULL
remove	NULL
the	NULL
cellular	NULL
debris	NULL
and	NULL
then	NULL
in	NULL
an	NULL
ultracentrifuge	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
100,000	NULL
g.	NULL
The	NULL
pellets	NULL
(	NULL
membrane	NULL
fractions	NULL
)	NULL
were	NULL
resuspended	NULL
in	NULL
extraction	NULL
buffer	NULL
containing	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
kept	NULL
for	NULL
30	NULL
minutes	NULL
on	NULL
ice	NULL
with	NULL
occasional	NULL
vortexing	NULL
,	NULL
after	NULL
which	NULL
they	NULL
were	NULL
centrifuged	NULL
for	NULL
10	NULL
minutes	NULL
in	NULL
a	NULL
microfuge	NULL
to	NULL
collect	NULL
the	NULL
super-natants	NULL
.	NULL

The	NULL
cytosolic	NULL
fractions	NULL
and	NULL
the	NULL
detergent-extracted	NULL
membrane	NULL
fractions	NULL
were	NULL
eluted	NULL
at	NULL
4°C	NULL
with	NULL
2	NULL
ml	NULL
elution	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris-HC	NULL
]	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
containing	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
EGTA	NULL
,	NULL
0.2	NULL
M	NULL
NaCl	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
B-mercaptoethanol	NULL
)	NULL
in	NULL
DEAE-cellulose	NULL
columns	NULL
.	NULL

PKC	NULL
activities	NULL
were	NULL
determined	NULL
with	NULL
the	NULL
Protein	NULL
Kinase	NULL
C	NULL
Assay	NULL
System	NULL
(	NULL
Gibco/BRL	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

This	NULL
assay	NULL
system	NULL
uses	NULL
as	NULL
phosphate	NULL
acceptor	NULL
the	NULL
myelin	NULL
basic	NULL
protein	NULL
sequence	NULL
Arg-Ser-Lys-Leu	NULL
(	NULL
MBP4-14	NULL
)	NULL
,	NULL
which	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
highly	NULL
specific	NULL
for	NULL
the	NULL
PKC-B	NULL
and	NULL
PKC	NULL
-y	NULL
subspecies	NULL
(	NULL
Yasuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Gel	NULL
retardation	NULL
assays	NULL
Nuclear	NULL
extracts	NULL
from	NULL
1-2x10	NULL
``	NULL
cells	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Schreibert	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Partially	NULL
complementary	NULL
oligonucleotide	NULL
pairs	NULL
were	NULL
synthesized	NULL
in	NULL
a	NULL
Gene	NULL
Assembler	NULL
Plus	NULL
(	NULL
Pharmacia	NULL
LKB	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
and	NULL
used	NULL
to	NULL
prepare	NULL
double-strand	NULL
oligonucleotides	NULL
containing	NULL
AP-1-	NULL
,	NULL
NF-KB-and	NULL
EGR-l-recognizing	NULL
sequences	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
:	NULL
for	NULL
AP-1	NULL
,	NULL
_	NULL
5-GGCTAGTGATGAGTCAAGCCGGATC-3	NULL
'	NULL
and	NULL
5'-GGGATCCGGCTTGACTCATCACTAG-3	NULL
'	NULL
;	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
5-GATC-GAGGGGACTTTCCCTAGC-3	NULL
'	NULL
and	NULL
5-GGGCTAGGGAAAGTCC-CCTCGA-3	NULL
'	NULL
,	NULL
and	NULL
for	NULL
EGR-1	NULL
5-GGATCCCGGCGCGGGGGC-GACGGCGT-3	NULL
'	NULL
and	NULL
5-GGACGCCCTCGCCCCCGCGc-CGGGAT-3	NULL
'	NULL
.	NULL

The	NULL
probes	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
&	NULL
-°°P	NULL
]	NULL
dCTP	NULL
following	NULL
the	NULL
method	NULL
of	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
for	NULL
15	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
case	NULL
of	NULL
AP-1	NULL
,	NULL
and	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
20°C	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NF-KB	NULL
and	NULL
EGR-1	NULL
,	NULL
in	NULL
20	NULL
pul	NULL
of	NULL
the	NULL
corresponding	NULL
binding	NULL
buffer	NULL
containing	NULL
5	NULL
ng	NULL
of	NULL
the	NULL
labeled	NULL
probe	NULL
,	NULL
8	NULL
ug	NULL
of	NULL
total	NULL
nuclear	NULL
proteins	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI	NULL
:	NULL
dC	NULL
)	NULL
,	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA	NULL
.	NULL

The	NULL
binding	NULL
buffers	NULL
were	NULL
:	NULL
for	NULL
AP-1	NULL
,	NULL
25	NULL
mM	NULL
NaCl	NULL
,	NULL
60	NULL
mM	NULL
KCl	NULL
,	NULL
2	NULL
mM	NULL
1,4-dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
2	NULL
%	NULL
Ficoll	NULL
,	NULL
0.1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.1	NULL
mg/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
,	NULL
25	NULL
mM	NULL
4-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1-piperazineethanesulfonic	NULL
acid	NULL
(	NULL
Hepes	NULL
)	NULL
,	NULL
pH	NULL
7.4	NULL
;	NULL
for	NULL
NF-KB	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
»	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
25	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.6	NULL
;	NULL
and	NULL
for	NULL
EGR-1	NULL
,	NULL
70	NULL
mM	NULL
KCI	NULL
,	NULL
5	NULL
rmiM	NULL
MgC12	NULL
,	NULL
0.1	NULL
mM	NULL
ZnCl	NULL
»	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.05	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
NP-40	NULL
,	NULL
12	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
1	NULL
mg/ml	NULL
BSA	NULL
,	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
specificity	NULL
of	NULL
binding	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
6	NULL
hours	NULL
with	NULL
15	NULL
nM	NULL
TPA	NULL
,	NULL
and	NULL
the	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
follows	NULL
:	NULL
in	NULL
the	NULL
case	NULL
of	NULL
AP-1	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
excess	NULL
unlabeled	NULL
probe	NULL
,	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
pul	NULL
polyclonal	NULL
anti-jun	NULL
antibody	NULL
or	NULL
pre-immune	NULL
serum	NULL
(	NULL
kindly	NULL
donated	NULL
by	NULL
Dr	NULL
R.	NULL
Bravo	NULL
,	NULL
Bristol-Myers	NULL
Squibb	NULL
,	NULL
Princeton	NULL
,	NULL
USA	NULL
)	NULL
;	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NF-KB	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
unlabeled	NULL
probe	NULL
,	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
ug	NULL
anti-NF-xB	NULL
p50	NULL
or	NULL
anti-NF-	NULL
«	NULL
B	NULL
p65	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
or	NULL
preimmune	NULL
serum	NULL
;	NULL
and	NULL
in	NULL
the	NULL
case	NULL
of	NULL
EGR-1	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
unlabeled	NULL
probe	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
in	NULL
4	NULL
%	NULL
polyacryl-amide	NULL
gels	NULL
,	NULL
and	NULL
the	NULL
gels	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

RESULTS	NULL
DNA	NULL
damage	NULL
and	NULL
apoptosis	NULL
Fig	NULL
.	NULL

1	NULL
shows	NULL
the	NULL
capacity	NULL
of	NULL
a	NULL
1	NULL
hour	NULL
pulse-treatment	NULL
with	NULL
etoposide	NULL
(	NULL
0.15	NULL
and	NULL
3	NULL
uM	NULL
)	NULL
and	NULL
ICRF-193	NULL
(	NULL
0.3	NULL
and	NULL
6	NULL
uM	NULL
)	NULL
to	NULL
cause	NULL
primary	NULL
,	NULL
topoisomerase-mediated	NULL
DNA	NULL
damage	NULL
in	NULL
U-937	NULL
cells	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
alkaline	NULL
elution	NULL
assays	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
0.15	NULL
uM	NULL
etoposide	NULL
,	NULL
which	NULL
as	NULL
indicated	NULL
below	NULL
is	NULL
a	NULL
subcytotoxic	NULL
concentration	NULL
,	NULL
sufficed	NULL
to	NULL
cause	NULL
detectable	NULL
DNA	NULL
breakage	NULL
.	NULL

At	NULL
a	NULL
concentration	NULL
of	NULL
3	NULL
uM	NULL
,	NULL
the	NULL
drug-produced	NULL
breakage	NULL
was	NULL
equivalent	NULL
to	NULL
more	NULL
than	NULL
10	NULL
Gy	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
ICRF-193	NULL
failed	NULL
to	NULL
provoke	NULL
DNA	NULL
breaks	NULL
at	NULL
all	NULL
concentrations	NULL
tested	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
etoposide	NULL
pulse-treatment	NULL
rapidly	NULL
induced	NULL
nucleosome-sized	NULL
DNA	NULL
degradation	NULL
and	NULL
changes	NULL
in	NULL
nuclear	NULL
structure	NULL
,	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
,	NULL
and	NULL
a	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
,	NULL
measured	NULL
by	NULL
cell	NULL
number	NULL
increase	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
none	NULL
of	NULL
these	NULL
effects	NULL
were	NULL
observed	NULL
in	NULL
cells	NULL
pulse-treated	NULL
with	NULL
ICRF-193	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
confirm	NULL
the	NULL
different	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
in	NULL
U-937	NULL
cells	NULL
,	NULL
as	NULL
earlier	NULL
demonstrated	NULL
in	NULL
other	NULL
cell	NULL
lines	NULL
(	NULL
Ishida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Beere	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
cycle	NULL
alterations	NULL
and	NULL
differentiation	NULL
induction	NULL
It	NULL
was	NULL
previously	NULL
demonstrated	NULL
that	NULL
continuous	NULL
treatments	NULL
with	NULL
subcytotoxic	NULL
concentrations	NULL
of	NULL
etoposide	NULL
and	NULL
other	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
which	NULL
generate	NULL
DNA	NULL
strand	NULL
breaks	NULL
(	NULL
amsacrine	NULL
,	NULL
doxorubicin	NULL
and	NULL
mitoxantrone	NULL
)	NULL
induced	NULL
U-937	NULL
cell	NULL
differentiation	NULL
(	NULL
Rius	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Pérez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
determine	NULL
whether	NULL
ICRF-193	NULL
,	NULL
which	NULL
did	NULL
not	NULL
cause	NULL
DNA	NULL
breakage	NULL
,	NULL
was	NULL
also	NULL
able	NULL
to	NULL
trigger	NULL
differen-	NULL
1.0	NULL
Q\	NULL
:	NULL
g	NULL
?	NULL

“	NULL
L_	NULL
zﬁ—Q	NULL
[	NULL
~	NULL
~	NULL
~~	NULL
o	NULL
a	NULL
.	NULL

~	NULL
=-	NULL
©	NULL
-y	NULL
_	NULL
ﬂ	NULL
?	NULL

|_	NULL
\	NULL
<	NULL
.	NULL

>	NULL
\	NULL
&	NULL
o	NULL
v	NULL
a	NULL
;	NULL
|	NULL
\	NULL
~	NULL
&	NULL
o	NULL
_	NULL
H	NULL
0	NULL
E	NULL
\-	NULL
*~	NULL
C	NULL
g	NULL
Cont	NULL
:	NULL
x	NULL
\	NULL
.	NULL

<	NULL
|	NULL
-	NULL
Etop	NULL
:	NULL
®	NULL
0.15	NULL
uM	NULL
;	NULL
®	NULL
3	NULL
uM	NULL
a	NULL
ICRF	NULL
:	NULL
0	NULL
0.3	NULL
uM	NULL
;	NULL
8	NULL
6	NULL
uM	NULL
X-rays	NULL
:	NULL
v	NULL
3	NULL
Gy	NULL
;	NULL
G	NULL
10	NULL
Gy	NULL
0.1	NULL
i	NULL
1	NULL
1	NULL
1	NULL
1	NULL
1	NULL
|	NULL
1	NULL
2	NULL
4	NULL
6	NULL
8	NULL
Hours	NULL
of	NULL
elution	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Alkaline	NULL
elution	NULL
profiles	NULL
of	NULL
DNA	NULL
from	NULL
U-937	NULL
cells	NULL
.	NULL

Cells	NULL
containing	NULL
°H-labeled	NULL
DNA	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
hour	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Cont	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
lysed	NULL
on	NULL
polycarbonate	NULL
filters	NULL
,	NULL
treated	NULL
with	NULL
proteinase	NULL
K	NULL
and	NULL
eluted	NULL
at	NULL
pH	NULL
12.1	NULL
.	NULL

X-irradiated	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
controls	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
determinations	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

Differentiation	NULL
by	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
-	NULL
339	NULL
tiation	NULL
.	NULL

Preliminary	NULL
assays	NULL
indicated	NULL
that	NULL
the	NULL
concentrations	NULL
of	NULL
(	NULL
0.15	NULL
uM	NULL
etoposide	NULL
and	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
decreased	NULL
U-937	NULL
cell	NULL
proliferation	NULL
to	NULL
a	NULL
similar	NULL
extent	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
upper	NULL
graph	NULL
)	NULL
.	NULL

At	NULL
the	NULL
third	NULL
day	NULL
of	NULL
treatment	NULL
more	NULL
than	NULL
80	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
excluded	NULL
trypan	NULL
blue	NULL
,	NULL
and	NULL
those	NULL
with	NULL
the	NULL
morphological	NULL
characteristics	NULL
of	NULL
apoptosis	NULL
only	NULL
amounted	NULL
to	NULL
23	NULL
%	NULL
and	NULL
14	NULL
%	NULL
in	NULL
etoposide-	NULL
and	NULL
ICRF-193-treated	NULL
cultures	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
concentrations	NULL
of	NULL
0.15	NULL
uM	NULL
etoposide	NULL
and	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
were	NULL
considered	NULL
to	NULL
be	NULL
subcytotoxic	NULL
and	NULL
adopted	NULL
for	NULL
further	NULL
experiments	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
both	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
increased	NULL
the	NULL
proportion	NULL
of	NULL
cells	NULL
with	NULL
4C	NULL
DNA	NULL
ICRF	NULL
E0	NULL
.	NULL

5	NULL
2	NULL
o	NULL
m	NULL
Etop	NULL
3	NULL
uM	NULL
4°	NULL
-o	NULL
ICRF	NULL
6	NULL
uM	NULL
Apoptotic	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
3	NULL
6	NULL
12	NULL
Hours	NULL
of	NULL
recovery	NULL
UJ	NULL
®	NULL
Etop	NULL
1	NULL
uM	NULL
10	NULL
®	NULL
Etop	NULL
3	NULL
uM	NULL
A	NULL
Etop	NULL
6	NULL
uM	NULL
-	NULL
_	NULL
0	NULL
ICRF	NULL
6	NULL
uM	NULL
R	NULL
A	NULL
CRFyﬁ/	NULL
5|-	NULL
xX	NULL
Cont	NULL
A	NULL
A	NULL
AZ	NULL
,	NULL
-	NULL
``	NULL
1	NULL
2	NULL
3	NULL
Days	NULL
of	NULL
recovery	NULL
Viable	NULL
cells	NULL
(	NULL
x	NULL
10-5	NULL
)	NULL
per	NULL
ml	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Effect	NULL
of	NULL
pulse-treatments	NULL
with	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
on	NULL
U-937	NULL
cell	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
hour	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Cont	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
,	NULL
and	NULL
then	NULL
allowed	NULL
to	NULL
recover	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
drugs	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
left	NULL
panel	NULL
shows	NULL
frequency	NULL
of	NULL
cells	NULL
with	NULL
condensed	NULL
or	NULL
fragmented	NULL
chromatin	NULL
at	NULL
different	NULL
times	NULL
of	NULL
recovery	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
DAPI	NULL
staining	NULL
and	NULL
microscope	NULL
examination	NULL
.	NULL

An	NULL
example	NULL
of	NULL
apoptotic	NULL
cells	NULL
at	NULL
hour	NULL
12	NULL
of	NULL
recovery	NULL
is	NULL
indicated	NULL
by	NULL
arrows	NULL
in	NULL
the	NULL
photograph	NULL
.	NULL

Bar	NULL
,	NULL
15	NULL
uum	NULL
.	NULL

The	NULL
right	NULL
panel	NULL
shows	NULL
DNA	NULL
fragmentation	NULL
at	NULL
hour	NULL
12	NULL
of	NULL
recovery	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
and	NULL
ethidium	NULL
bromide	NULL
staining	NULL
.	NULL

The	NULL
horizontal	NULL
lines	NULL
at	NULL
the	NULL
margin	NULL
indicate	NULL
the	NULL
position	NULL
of	NULL
simultaneously	NULL
run	NULL
markers	NULL
(	NULL
from	NULL
top	NULL
to	NULL
bottom	NULL
:	NULL
3.76	NULL
,	NULL
1.93	NULL
,	NULL
1.26	NULL
and	NULL
0.70	NULL
kb	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cell	NULL
proliferation	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
at	NULL
different	NULL
times	NULL
of	NULL
recovery	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
at	NULL
least	NULL
two	NULL
determinations	NULL
,	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

340	NULL
-	NULL
C.	NULL
Pérez	NULL
and	NULL
others	NULL
J	NULL
>	NULL
UJ	NULL
®	NULL
Etop	NULL
0.05	NULL
uM	NULL
x	NULL
2:0	NULL
Etop	NULL
2C	NULL
ICRF	NULL
-_	NULL
®	NULL
Etop	NULL
0.15	NULL
uM	NULL
a	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
continuous	NULL
treatments	NULL
with	NULL
etoposide	NULL
E	NULL
10	NULL
|-	NULL
A	NULL
Etop	NULL
0.3	NULL
uM	NULL
L	NULL
o	NULL
and	NULL
ICRF-193	NULL
on	NULL
U-937	NULL
cell	NULL
proliferation	NULL
,	NULL
cell	NULL
cycle	NULL
§	NULL
8	NULL
ESE	NULL
8:13	NULL
ﬁm	NULL
é	NULL
E	NULL
4C	NULL
and	NULL
cell	NULL
size	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
upper	NULL
graph	NULL
represents	NULL
cell	NULL
3	NULL
-	NULL
aA	NULL
iCRF	NULL
0.6	NULL
uM	NULL
3	NULL
proliferation	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
x	NULL
X	NULL
Cont	NULL
a	NULL
=	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
.	NULL

The	NULL
lower	NULL
graph	NULL
represents	NULL
the	NULL
_	NULL
2	NULL
|_	NULL
*	NULL
é	NULL
!	NULL

t	NULL
proportion	NULL
of	NULL
cells	NULL
with	NULL
nuclear	NULL
morphology	NULL
g	NULL
5	NULL
/	NULL
m	NULL
9	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Distribution	NULL
of	NULL
cells	NULL
in	NULL
<	NULL
/	NULL
9	NULL
é	NULL
DNA	NULL
content	NULL
relation	NULL
to	NULL
DNA	NULL
content	NULL
in	NULL
untreated	NULL
cultures	NULL
(	NULL
dotted	NULL
S	NULL
|-	NULL
/	NULL
A	NULL
C	NULL
lines	NULL
)	NULL
and	NULL
cultures	NULL
treated	NULL
for	NULL
72	NULL
hours	NULL
with	NULL
either	NULL
r	NULL
/Atﬁ	NULL
0.15	NULL
uM	NULL
etoposide	NULL
or	NULL
0.3	NULL
M	NULL
ICRF-193	NULL
(	NULL
continuous	NULL
1	NULL
P	NULL
1	NULL
2C	NULL
4C	NULL
lines	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Relative	NULL
cell	NULL
size	NULL
,	NULL
measured	NULL
by	NULL
the	NULL
ratio	NULL
of	NULL
Ca	NULL
L	NULL
protein	NULL
content	NULL
to	NULL
DNA	NULL
content	NULL
,	NULL
in	NULL
the	NULL
'2C	NULL
'	NULL
and	NULL
'4C	NULL
``	NULL
'	NULL
2	NULL
20	NULL
|-	NULL
®	NULL
E	NULL
subpopulations	NULL
from	NULL
untreated	NULL
cultures	NULL
(	NULL
dotted	NULL
lines	NULL
)	NULL
3	NULL
/	NULL
0	NULL
3	NULL
Pow	NULL
and	NULL
from	NULL
cultures	NULL
treated	NULL
for	NULL
72	NULL
hours	NULL
with	NULL
either	NULL
0.15	NULL
g	NULL
10	NULL
}	NULL
/8/	NULL
=	NULL
+7	NULL
{	NULL
I	NULL
\	NULL
M	NULL
etoposide	NULL
(	NULL
continuous	NULL
lines	NULL
)	NULL
or	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
&	NULL
Eé§4X——X	NULL
8	NULL
*	NULL
9	NULL
‘	NULL
n	NULL
‘	NULL
J	NULL
#	NULL
\\	NULL
(	NULL
broken	NULL
lines	NULL
)	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
at	NULL
least	NULL
two	NULL
determinations	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

content	NULL
and	NULL
provoked	NULL
positive	NULL
unbalanced	NULL
cell	NULL
growth	NULL
,	NULL
namely	NULL
excess	NULL
of	NULL
cell	NULL
mass	NULL
,	NULL
measured	NULL
as	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
ratio	NULL
of	NULL
total	NULL
protein	NULL
content	NULL
versus	NULL
total	NULL
DNA	NULL
content	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Differentiation	NULL
was	NULL
determined	NULL
by	NULL
measuring	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
CD11b/CD18	NULL
(	NULL
Hickstein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
and	NULL
CD11c/CD18	NULL
(	NULL
Dudley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
leukocyte	NULL
integrins	NULL
,	NULL
the	NULL
reduction	NULL
of	NULL
NBT	NULL
(	NULL
Collins	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
,	NULL
and	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
intermediate	NULL
filament	NULL
vimentin	NULL
(	NULL
Rius	NULL
and	NULL
Aller	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
indicate	NULL
that	NULL
,	NULL
in	NULL
spite	NULL
of	NULL
their	NULL
different	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
both	NULL
ICRF-193	NULL
and	NULL
etoposide	NULL
induced	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
differentiation	NULL
markers	NULL
.	NULL

At	NULL
the	NULL
used	NULL
concentrations	NULL
,	NULL
their	NULL
expression	NULL
was	NULL
more	NULL
rapid	NULL
in	NULL
etoposide-treated	NULL
cells	NULL
than	NULL
in	NULL
ICRF-193-treated	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
activity	NULL
Earlier	NULL
works	NULL
indicated	NULL
that	NULL
myeloid	NULL
differentiation	NULL
inducers	NULL
(	NULL
Makowske	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Ahihara	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
as	NULL
well	NULL
as	NULL
DNA	NULL
damaging	NULL
agents	NULL
(	NULL
Posada	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Rubin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
stimulated	NULL
PKC	NULL
activity	NULL
.	NULL

For	NULL
these	NULL
reasons	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
measure	NULL
PKC	NULL
activity	NULL
in	NULL
U-937	NULL
cells	NULL
induced	NULL
to	NULL
differentiate	NULL
with	NULL
0.15	NULL
LM	NULL
etoposide	NULL
and	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
.	NULL

The	NULL
results	NULL
are	NULL
represented	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Etoposide	NULL
produced	NULL
an	NULL
early	NULL
,	NULL
transient	NULL
activation	NULL
of	NULL
membrane-bound	NULL
PKC	NULL
(	NULL
from	NULL
hours	NULL
1	NULL
to	NULL
6	NULL
)	NULL
.	NULL

Such	NULL
an	NULL
activation	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
involve	NULL
enzyme	NULL
translocation	NULL
from	NULL
cytosol	NULL
to	NULL
membranes	NULL
,	NULL
since	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
cytosolic	NULL
fraction	NULL
remained	NULL
unaltered	NULL
.	NULL

This	NULL
contrasts	NULL
with	NULL
the	NULL
action	NULL
of	NULL
the	NULL
phorbol	NULL
ester	NULL
TPA	NULL
,	NULL
a	NULL
powerful	NULL
differentiation	NULL
inducer	NULL
of	NULL
myeloid	NULL
cells	NULL
(	NULL
Collins	NULL
,	NULL
1987	NULL
)	NULL
which	NULL
causes	NULL
PKC	NULL
activation	NULL
by	NULL
eliciting	NULL
enzyme	NULL
translocation	NULL
(	NULL
Mezetti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
,	NULL
and	NULL
results	NULL
in	NULL
this	NULL
work	NULL
)	NULL
.	NULL

Instead	NULL
,	NULL
etoposide	NULL
might	NULL
selectively	NULL
activate	NULL
the	NULL
pool	NULL
of	NULL
inactive	NULL
enzyme	NULL
residing	NULL
on	NULL
the	NULL
membrane	NULL
,	NULL
as	NULL
has	NULL
been	NULL
described	NULL
in	NULL
DMSO-treated	NULL
myeloid	NULL
cells	NULL
(	NULL
Durkin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Whatever	NULL
the	NULL
case	NULL
,	NULL
the	NULL
early	NULL
PKC	NULL
activation	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ICRF-193	NULL
.	NULL

However	NULL
,	NULL
the	NULL
two	NULL
topoisomerase	NULL
inhibitors	NULL
stimulated	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
total	NULL
,	NULL
membrane-bound	NULL
plus	NULL
cytosolic	NULL
enzyme	NULL
,	NULL
when	NULL
applied	NULL
for	NULL
prolonged	NULL
treatment	NULL
periods	NULL
(	NULL
48	NULL
hours	NULL
in	NULL
the	NULL
case	NULL
of	NULL
etoposide	NULL
and	NULL
72	NULL
hours	NULL
in	NULL
the	NULL
case	NULL
of	NULL
ICRF-193	NULL
)	NULL
.	NULL

Transcription	NULL
factor	NULL
activity	NULL
It	NULL
was	NULL
earlier	NULL
reported	NULL
that	NULL
DNA	NULL
damaging	NULL
agents	NULL
stimulated	NULL
1	NULL
2	NULL
3	NULL
Days	NULL
of	NULL
treatment	NULL
Ratio	NULL
protein/	NULL
ONA	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
Jun/AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
EGR-1	NULL
(	NULL
Brach	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Hallahan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Rubin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
transcription	NULL
factors	NULL
seemed	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
differentiation	NULL
induction	NULL
of	NULL
myeloid	NULL
cells	NULL
by	NULL
TPA	NULL
(	NULL
Hass	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

For	NULL
these	NULL
reasons	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
examine	NULL
the	NULL
binding	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
in	NULL
U-937	NULL
cells	NULL
treated	NULL
for	NULL
3	NULL
to	NULL
48	NULL
hours	NULL
with	NULL
0.15	NULL
uM	NULL
etoposide	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

The	NULL
treatment	NULL
elicited	NULL
a	NULL
great	NULL
though	NULL
transient	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
,	NULL
with	NULL
a	NULL
maximum	NULL
value	NULL
at	NULL
hour	NULL
12	NULL
of	NULL
treatment	NULL
,	NULL
A	NULL
CD11b	NULL
®	NULL
Etop	NULL
0	NULL
ICRF	NULL
_	NULL
.	NULL

@	NULL
x	NULL
Cont	NULL
,	NULL
@	NULL
0	NULL
/	NULL
o/	NULL
/o	NULL
0	NULL
o	NULL
``	NULL
1	NULL
2	NULL
3	NULL
Days	NULL
of	NULL
treatment	NULL
ler	NULL
le	NULL
]	NULL
p	NULL
0	NULL
e	NULL
o	NULL
Positive	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
€	NULL
kDa	NULL
E	NULL
$	NULL
&	NULL
k	NULL
3	NULL
ii	NULL
S	NULL
g	NULL
97	NULL
a	NULL
66	NULL
(	NULL
@	NULL
]	NULL
1	NULL
2	NULL
3	NULL
ap-	NULL
Days	NULL
of	NULL
treatment	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Expression	NULL
of	NULL
differentiation	NULL
markers	NULL
in	NULL
untreated	NULL
U-937	NULL
cells	NULL
(	NULL
Cont	NULL
)	NULL
and	NULL
cells	NULL
incubated	NULL
with	NULL
0.15	NULL
M	NULL
etoposide	NULL
or	NULL
0.3	NULL
uM	NULL
ICRFE-193	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Percentage	NULL
of	NULL
cells	NULL
with	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
CD11b/CD18	NULL
and	NULL
CD11c/CD18	NULL
leukocyte	NULL
integrins	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
combined	NULL
with	NULL
flow	NULL
cytometry	NULL
.	NULL

(	NULL
B	NULL
)	NULL
NBT	NULL
reduction	NULL
to	NULL
formazan	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
spectrometry	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Accumulation	NULL
of	NULL
the	NULL
intermediate	NULL
filament	NULL
protein	NULL
vimentin	NULL
at	NULL
hour	NULL
72	NULL
of	NULL
treatment	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
immunoblot	NULL
assay	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

Membrane	NULL
e	NULL
-	NULL
°	NULL
0	NULL
a	NULL
/	NULL
=-	NULL
O	NULL
oj	NULL
wo	NULL
``	NULL
&	NULL
97	NULL
.	NULL

0	NULL
t=	NULL
E	NULL
O	NULL
Cytosol	NULL
o	NULL
€	NULL
2201	NULL
»	NULL
J—	NULL
o	NULL
&	NULL
0	NULL
>	NULL
®	NULL
Etop	NULL
J	NULL
-A	NULL
=	NULL
159	NULL
T-	NULL
o	NULL
ioRF	NULL
f	NULL
H	NULL
x	NULL
Cont	NULL
o	NULL
?	NULL

f	NULL
_A*	NULL
80	NULL
a.	NULL
a_	NULL
\:8:8	NULL
,	NULL
¢8	NULL
\g	NULL
_9¢°	NULL
\	NULL
60	NULL
x	NULL
TL	NULL
U	NULL
ps	NULL
|	NULL
DL	NULL
p	NULL
ps	NULL
1	NULL
3	NULL
6	NULL
12	NULL
24	NULL
48	NULL
72	NULL
96	NULL
Hours	NULL
of	NULL
treatment	NULL
preceding	NULL
the	NULL
expression	NULL
of	NULL
differentiation	NULL
markers	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
EGR-1	NULL
was	NULL
only	NULL
slightly	NULL
increased	NULL
at	NULL
hours	NULL
12	NULL
and	NULL
24	NULL
(	NULL
a	NULL
twofold	NULL
increase	NULL
,	NULL
approximately	NULL
)	NULL
,	NULL
and	NULL
that	NULL
of	NULL
NF-KB	NULL
was	NULL
not	NULL
significantly	NULL
affected	NULL
.	NULL

The	NULL
stimulation	NULL
of	NULL
AP-1	NULL
was	NULL
paralleled	NULL
by	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
c-jun	NULL
and	NULL
c-fos	NULL
protooncogenes	NULL
,	NULL
which	NULL
encode	NULL
protein	NULL
con	NULL
A	NULL
Differentiation	NULL
by	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
-	NULL
341	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
on	NULL
PKC	NULL
activity	NULL
.	NULL

The	NULL
graphs	NULL
represent	NULL
the	NULL
membrane-bound	NULL
and	NULL
cytosolic	NULL
PKC	NULL
activities	NULL
upon	NULL
1	NULL
hour	NULL
tratment	NULL
with	NULL
15	NULL
nM	NULL
TPA	NULL
,	NULL
and	NULL
at	NULL
different	NULL
times	NULL
of	NULL
treatment	NULL
with	NULL
0.15	NULL
uM	NULL
etoposide	NULL
and	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
.	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
at	NULL
least	NULL
three	NULL
determinations	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

stituents	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
,	NULL
and	NULL
followed	NULL
by	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
AP-1	NULL
regulated	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
col-lagenase	NULL
and	NULL
TNF-	NULL
@	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Measurements	NULL
of	NULL
transcription	NULL
factor	NULL
activities	NULL
in	NULL
cells	NULL
induced	NULL
to	NULL
differentiate	NULL
with	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
revealed	NULL
that	NULL
this	NULL
agent	NULL
also	NULL
stimulated	NULL
AP-1	NULL
binding	NULL
,	NULL
albeit	NULL
at	NULL
a	NULL
later	NULL
time	NULL
(	NULL
48	NULL
hours	NULL
)	NULL
than	NULL
in	NULL
the	NULL
case	NULL
of	NULL
etoposide	NULL
.	NULL

ICRF-193	NULL
failed	NULL
to	NULL
significantly	NULL
increase	NULL
NF-KB	NULL
and	NULL
EGR-1	NULL
binding	NULL
activities	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
results	NULL
demonstrate	NULL
that	NULL
pulse-treatment	NULL
of	NULL
U-937	NULL
promonocytic	NULL
cells	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
etoposide	NULL
cause	NULL
topoisomerase-mediated	NULL
DNA	NULL
breakage	NULL
,	NULL
which	NULL
is	NULL
rapidly	NULL
followed	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
and	NULL
the	NULL
inhibition	NULL
of	NULL
proliferation	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
none	NULL
of	NULL
these	NULL
effects	NULL
are	NULL
provoked	NULL
by	NULL
pulse-treatment	NULL
with	NULL
ICRF-193	NULL
.	NULL

These	NULL
observations	NULL
confirm	NULL
the	NULL
different	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
in	NULL
U-937	NULL
cells	NULL
,	NULL
as	NULL
previously	NULL
demonstrated	NULL
in	NULL
RPMI	NULL
8402	NULL
T	NULL
lymphoblastoid	NULL
cells	NULL
(	NULL
Ishida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
HL-60	NULL
promyelocytic	NULL
cells	NULL
(	NULL
Beere	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
Etop	NULL
(	NULL
h	NULL
}	NULL
ICRF	NULL
(	NULL
h	NULL
)	NULL
TPA	NULL
omousTt	NULL
o	NULL
Oud	NULL
O	NULL
wb	NULL
gm	NULL
od	NULL
-o	NULL
smo	NULL
=	NULL
>	NULL
,	NULL
a	NULL
a	NULL
wan	NULL
.	NULL

0	NULL
®	NULL
a	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
topoisomerase	NULL
inhibitors	NULL
on	NULL
AP-1	NULL
(	NULL
A	NULL
)	NULL
,	NULL
EGR-1	NULL
(	NULL
B	NULL
)	NULL
and	NULL
NF-KB	NULL
(	NULL
C	NULL
)	NULL
binding	NULL
activities	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
with	NULL
0.15	NULL
M	NULL
etoposide	NULL
or	NULL
0.3	NULL
uM	NULL
ICRF-193	NULL
were	NULL
used	NULL
for	NULL
gel	NULL
retardation	NULL
assays	NULL
.	NULL

As	NULL
controls	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
for	NULL
6	NULL
hours	NULL
with	NULL
15	NULL
nM	NULL
TPA	NULL
were	NULL
assayed	NULL
under	NULL
the	NULL
following	NULL
conditions	NULL
:	NULL
for	NULL
AP-1	NULL
,	NULL
in	NULL
the	NULL
B	NULL
__	NULL
{	NULL
tt	NULL
Etop	NULL
(	NULL
h	NULL
)	NULL
TPA	NULL
C	NULL
Etop	NULL
(	NULL
h	NULL
}	NULL
b	NULL
AAs	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
of	NULL
50-fold	NULL
molar	NULL
excess	NULL
unlabeled	NULL
probe	NULL
,	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
anti-Jun	NULL
antibody	NULL
(	NULL
Jun	NULL
)	NULL
or	NULL
a	NULL
pre-immune	NULL
serum	NULL
(	NULL
PS	NULL
)	NULL
;	NULL
for	NULL
EGR-1	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
of	NULL
50-fold	NULL
molar	NULL
excess	NULL
unlabeled	NULL
probe	NULL
;	NULL
and	NULL
for	NULL
NF-KB	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
of	NULL
50-fold	NULL
molar	NULL
excess	NULL
unlabeled	NULL
probe	NULL
,	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-p65	NULL
(	NULL
p65	NULL
)	NULL
or	NULL
anti-p50	NULL
(	NULL
p50	NULL
)	NULL
antibodies	NULL
,	NULL
or	NULL
pre-immune	NULL
serum	NULL
(	NULL
PS	NULL
)	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
thin	NULL
arrows	NULL
,	NULL
and	NULL
free	NULL
oligoprobe	NULL
by	NULL
thick	NULL
arrows	NULL
.	NULL

The	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
at	NULL
least	NULL
two	NULL
determinations	NULL
.	NULL

A	NULL
certain	NULL
variation	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
bands	NULL
was	NULL
observed	NULL
in	NULL
different	NULL
NF-KB	NULL
binding	NULL
assays	NULL
.	NULL

ECB	NULL
R4	NULL
-	NULL
{	NULL
.	NULL

-=-	NULL
Wo	NULL
thik	NULL
sh	NULL
WP	NULL
O0	NULL
tag	NULL
'	NULL
TPA	NULL
O	NULL
iD	NULL
D	NULL
mw	NULL
ag	NULL
o	NULL
om	NULL
w	NULL
o	NULL
s	NULL
o	NULL
a	NULL
9	NULL
1	NULL
=O	NULL
-	NULL
p	NULL
-ag	NULL
-+	NULL
a	NULL
an	NULL
50-p65	NULL
T	NULL
«	NULL
-	NULL
PPV	NULL
-P	NULL
a	NULL
by	NULL
24	NULL
.	NULL

€	NULL
!	NULL

WW	NULL
«	NULL
@	NULL
-	NULL
p50-p50	NULL
ii	NULL
n	NULL
ddidin	NULL
ii	NULL
(	NULL
ig	NULL
342	NULL
C.	NULL
Pérez	NULL
and	NULL
others	NULL
have	NULL
also	NULL
reported	NULL
a	NULL
different	NULL
action	NULL
of	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
on	NULL
cell	NULL
cycle	NULL
progression	NULL
from	NULL
G2	NULL
to	NULL
mitosis	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
(	NULL
Ishida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

It	NULL
must	NULL
be	NULL
noted	NULL
that	NULL
prolonged	NULL
treatments	NULL
with	NULL
differentiation-inducing	NULL
concentrations	NULL
of	NULL
both	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
caused	NULL
the	NULL
death	NULL
by	NULL
apoptosis	NULL
of	NULL
a	NULL
small	NULL
fraction	NULL
of	NULL
cells	NULL
.	NULL

Nevertheless	NULL
,	NULL
under	NULL
these	NULL
conditions	NULL
apoptosis	NULL
might	NULL
be	NULL
a	NULL
process	NULL
associated	NULL
with	NULL
cell	NULL
differentiation	NULL
,	NULL
as	NULL
earlier	NULL
reported	NULL
(	NULL
Cotter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
or	NULL
a	NULL
secondary	NULL
response	NULL
to	NULL
specific	NULL
cell	NULL
cycle	NULL
perturbation	NULL
,	NULL
as	NULL
discussed	NULL
below	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
the	NULL
differencies	NULL
in	NULL
the	NULL
primary	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
both	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
differentiation	NULL
markers	NULL
in	NULL
U-937	NULL
cells	NULL
.	NULL

This	NULL
result	NULL
rules	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
differentiation	NULL
could	NULL
merely	NULL
be	NULL
a	NULL
response	NULL
to	NULL
the	NULL
DNA	NULL
breakage	NULL
produced	NULL
by	NULL
classical	NULL
anti-topoisomerase	NULL
drugs	NULL
.	NULL

A	NULL
possible	NULL
explanation	NULL
migth	NULL
be	NULL
that	NULL
topoisomerase	NULL
inhibition	NULL
itself	NULL
triggers	NULL
differentiation	NULL
,	NULL
as	NULL
earlier	NULL
proposed	NULL
by	NULL
Nakaya	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
this	NULL
hypothesis	NULL
must	NULL
be	NULL
considered	NULL
with	NULL
caution	NULL
,	NULL
since	NULL
there	NULL
are	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
,	NULL
such	NULL
as	NULL
aclarubicin	NULL
,	NULL
which	NULL
failed	NULL
to	NULL
induced	NULL
U-937	NULL
cell	NULL
differentiation	NULL
(	NULL
Pérez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

As	NULL
an	NULL
alternative	NULL
expla-nation	NULL
,	NULL
Wangenheim	NULL
and	NULL
Howard	NULL
(	NULL
1978	NULL
)	NULL
proposed	NULL
that	NULL
differentiation	NULL
may	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
generation	NULL
of	NULL
'unbal-anced	NULL
growth	NULL
'	NULL
,	NULL
defined	NULL
as	NULL
an	NULL
abnormally	NULL
high	NULL
ratio	NULL
of	NULL
cell	NULL
mass	NULL
to	NULL
DNA	NULL
content	NULL
.	NULL

This	NULL
hypothesis	NULL
seems	NULL
to	NULL
be	NULL
corroborated	NULL
by	NULL
the	NULL
results	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
which	NULL
shows	NULL
a	NULL
correlation	NULL
between	NULL
production	NULL
of	NULL
unbalanced	NULL
growth	NULL
and	NULL
differentiation	NULL
induction	NULL
by	NULL
several	NULL
types	NULL
of	NULL
cytostatic	NULL
drugs	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
generation	NULL
of	NULL
unbalanced	NULL
growth	NULL
was	NULL
also	NULL
proposed	NULL
by	NULL
other	NULL
authors	NULL
as	NULL
a	NULL
cause	NULL
of	NULL
apoptosis	NULL
(	NULL
Kung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Rubin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
an	NULL
integrative	NULL
hypothesis	NULL
is	NULL
that	NULL
the	NULL
disruption	NULL
of	NULL
cell	NULL
cycle	NULL
events	NULL
caused	NULL
by	NULL
some	NULL
topoisomerase	NULL
inhibitors	NULL
and	NULL
other	NULL
cytostatic	NULL
drugs	NULL
forces	NULL
the	NULL
cells	NULL
to	NULL
leave	NULL
the	NULL
proliferation	NULL
program	NULL
and	NULL
enter	NULL
into	NULL
differentiation	NULL
or	NULL
apoptosis	NULL
.	NULL

The	NULL
elected	NULL
pathway	NULL
probably	NULL
depends	NULL
on	NULL
the	NULL
particular	NULL
circumstance	NULL
of	NULL
each	NULL
cell	NULL
and	NULL
the	NULL
severity	NULL
of	NULL
the	NULL
treatment	NULL
.	NULL

The	NULL
possibility	NULL
that	NULL
PKC	NULL
could	NULL
mediate	NULL
differentiation	NULL
by	NULL
anti-topoisomerase	NULL
drugs	NULL
was	NULL
earlier	NULL
suggested	NULL
by	NULL
Constantinou	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
,	NULL
who	NULL
showed	NULL
that	NULL
novobiocin	NULL
caused	NULL
differentiation	NULL
of	NULL
TPA-sensitive	NULL
but	NULL
not	NULL
of	NULL
TPA-resistant	NULL
HL-60	NULL
cells	NULL
,	NULL
and	NULL
that	NULL
the	NULL
PKC	NULL
inhibitor	NULL
H7	NULL
prevented	NULL
the	NULL
induction	NULL
of	NULL
differentiation	NULL
by	NULL
novobiocin	NULL
.	NULL

Our	NULL
results	NULL
directly	NULL
demonstrate	NULL
Table	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
cytostatic	NULL
agents	NULL
on	NULL
cell	NULL
cycle	NULL
,	NULL
cell	NULL
mass	NULL
and	NULL
differentiation	NULL
of	NULL
U-937	NULL
cells	NULL
Primary	NULL
Accumulation	NULL
Increase	NULL
Drugs*	NULL
effect	NULL
of	NULL
cells	NULL
in	NULL
in	NULL
mass	NULL
_	NULL
Differ	NULL
.	NULL

fAmsacrine	NULL
Topo	NULL
II	NULL
inhib	NULL
.	NULL

Gz/M	NULL
Yes	NULL
Yes	NULL
#	NULL
Mitoxantrone	NULL
Topo	NULL
II	NULL
inhib	NULL
.	NULL

Gz/M	NULL
Yes	NULL
Yes	NULL
#	NULL
Doxorubicin	NULL
Topo	NULL
II	NULL
inhib	NULL
.	NULL

Gy/M	NULL
Yes	NULL
Yes	NULL
$	NULL
Aclarubicin	NULL
Topo	NULL
II	NULL
inhib	NULL
.	NULL

Slightly	NULL
Gy/M	NULL
No	NULL
No	NULL
Topo	NULL
II	NULL
inhib	NULL
.	NULL

Mainly	NULL
G1	NULL
No	NULL
Poor	NULL
§Camptothecin	NULL
_	NULL
Topo	NULL
I	NULL
inhib	NULL
.	NULL

Gz/M	NULL
Yes	NULL
Yes	NULL
[	NULL
Hydroxyurea	NULL
DNA	NULL
synt	NULL
.	NULL

inhib	NULL
.	NULL

Early	NULL
S	NULL
Yes	NULL
Yes	NULL
||Cisplatin	NULL
DNA	NULL
alkylation	NULL
Gy/M	NULL
Yes	NULL
Yes	NULL
*	NULL
Applied	NULL
for	NULL
72	NULL
hours	NULL
at	NULL
subcytotoxic	NULL
concentrations	NULL
.	NULL

{	NULL
Rius	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

{	NULL
Pérez	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

§Aller	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

[	NULL
Mata	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
,	NULL
and	NULL
unpublished	NULL
observations	NULL
.	NULL

|	NULL
[	NULL
Ballester	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

that	NULL
both	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
stimulate	NULL
the	NULL
total	NULL
,	NULL
membrane-bound	NULL
plus	NULL
cytosolic	NULL
enzyme	NULL
in	NULL
the	NULL
long	NULL
term	NULL
.	NULL

Such	NULL
a	NULL
late	NULL
activation	NULL
of	NULL
PKC	NULL
,	NULL
which	NULL
was	NULL
also	NULL
observed	NULL
with	NULL
other	NULL
differentiation	NULL
inducers	NULL
(	NULL
Makowske	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Aihara	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
,	NULL
could	NULL
represent	NULL
a	NULL
requirement	NULL
for	NULL
the	NULL
progression	NULL
of	NULL
differentiation	NULL
(	NULL
Aihara	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
etoposide	NULL
caused	NULL
an	NULL
early	NULL
,	NULL
transient	NULL
stimulation	NULL
of	NULL
membrane-bound	NULL
PKC	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
similar	NULL
response	NULL
was	NULL
elicited	NULL
by	NULL
typical	NULL
differentiation	NULL
inducers	NULL
such	NULL
as	NULL
TPA	NULL
and	NULL
DMSO	NULL
(	NULL
Mezetti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Durkin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
it	NULL
,	NULL
early	NULL
PKC	NULL
activation	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
requirement	NULL
for	NULL
differentiation	NULL
,	NULL
since	NULL
it	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
differentiation-inducing	NULL
concentrations	NULL
of	NULL
ICRF-193	NULL
.	NULL

Instead	NULL
,	NULL
it	NULL
might	NULL
represent	NULL
a	NULL
response	NULL
to	NULL
the	NULL
drug-generated	NULL
DNA	NULL
breakage	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
a	NULL
similar	NULL
result	NULL
was	NULL
obtained	NULL
upon	NULL
treatment	NULL
of	NULL
myeloid	NULL
cells	NULL
with	NULL
other	NULL
DNA	NULL
damaging	NULL
agents	NULL
(	NULL
Hallahan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Ballester	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
present	NULL
results	NULL
demonstrate	NULL
that	NULL
subcytotoxic	NULL
,	NULL
differentiation-inducing	NULL
concentrations	NULL
of	NULL
etoposide	NULL
and	NULL
ICREF-193	NULL
greatly	NULL
stimulate	NULL
AP-1	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
observation	NULL
supports	NULL
earlier	NULL
conclusions	NULL
on	NULL
the	NULL
importance	NULL
of	NULL
AP-1-regulated	NULL
genes	NULL
for	NULL
the	NULL
differentiation	NULL
of	NULL
myeloid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
treatments	NULL
caused	NULL
a	NULL
poor	NULL
stimulation	NULL
of	NULL
EGR-1	NULL
binding	NULL
and	NULL
null	NULL
stimulation	NULL
of	NULL
NF-KB	NULL
binding	NULL
,	NULL
which	NULL
contrasts	NULL
with	NULL
the	NULL
great	NULL
activation	NULL
caused	NULL
by	NULL
the	NULL
differentiation	NULL
inducer	NULL
TPA	NULL
(	NULL
Hass	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
response	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
depends	NULL
on	NULL
the	NULL
inducer	NULL
used	NULL
,	NULL
and	NULL
that	NULL
NF-KB	NULL
(	NULL
and	NULL
also	NULL
probably	NULL
EGR-1	NULL
)	NULL
are	NULL
not	NULL
neccessarily	NULL
involved	NULL
in	NULL
the	NULL
differentiation	NULL
induction	NULL
of	NULL
promonocytic	NULL
cells	NULL
.	NULL

It	NULL
must	NULL
be	NULL
noted	NULL
that	NULL
high	NULL
concentrations	NULL
of	NULL
etoposide	NULL
(	NULL
3	NULL
uM	NULL
or	NULL
more	NULL
)	NULL
stimulated	NULL
NF-KB	NULL
binding	NULL
in	NULL
HL-60	NULL
(	NULL
Bessho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
U-937	NULL
cells	NULL
(	NULL
L.	NULL
Garcia-Bermejo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
)	NULL
.	NULL

However	NULL
,	NULL
under	NULL
these	NULL
conditions	NULL
the	NULL
drug	NULL
rapidly	NULL
induces	NULL
apoptosis	NULL
instead	NULL
of	NULL
differentiation	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
it	NULL
is	NULL
concluded	NULL
that	NULL
DNA	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
may	NULL
cause	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
,	NULL
independently	NULL
of	NULL
their	NULL
capacity	NULL
to	NULL
generate	NULL
DNA	NULL
strand	NULL
breaks	NULL
.	NULL

Differentiation	NULL
is	NULL
probably	NULL
facilitated	NULL
by	NULL
the	NULL
cell	NULL
cycle	NULL
perturbations	NULL
caused	NULL
by	NULL
the	NULL
drugs	NULL
.	NULL

However	NULL
,	NULL
there	NULL
are	NULL
effects	NULL
,	NULL
such	NULL
as	NULL
the	NULL
rapid	NULL
induction	NULL
of	NULL
apoptosis	NULL
or	NULL
the	NULL
early	NULL
activation	NULL
of	NULL
PKC	NULL
,	NULL
which	NULL
seem	NULL
to	NULL
be	NULL
derived	NULL
from	NULL
the	NULL
production	NULL
of	NULL
primary	NULL
DNA	NULL
breakage	NULL
by	NULL
some	NULL
anti-topoisomerase	NULL
drugs	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
DGICYT	NULL
(	NULL
Spain	NULL
)	NULL
grant	NULL
PB94-0063	NULL
,	NULL
FIss	NULL
(	NULL
Spain	NULL
)	NULL
grant	NULL
94/0008-01	NULL
,	NULL
and	NULL
CAM	NULL
(	NULL
Spain	NULL
)	NULL
Grant	NULL
AEOO0419/95	NULL
.	NULL

L.G-B	NULL
.	NULL

was	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Comunidad	NULL
Autonoma	NULL
de	NULL
Castilla	NULL
La	NULL
Mancha	NULL
.	NULL

REFERENCES	NULL
Aihara	NULL
,	NULL
H.	NULL
,	NULL
Asaoka	NULL
,	NULL
Y.	NULL
,	NULL
Yoshida	NULL
,	NULL
K.	NULL
and	NULL
Nishikuza	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Sustained	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
is	NULL
essential	NULL
to	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
to	NULL
macrophage	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
11062-11066	NULL
.	NULL

Aller	NULL
,	NULL
P.	NULL
,	NULL
Rius	NULL
,	NULL
C.	NULL
,	NULL
Mata	NULL
,	NULL
EF	NULL
.	NULL

,	NULL
Zorrilla	NULL
,	NULL
A.	NULL
,	NULL
Cabafias	NULL
,	NULL
C.	NULL
,	NULL
Bellon	NULL
,	NULL
T.	NULL
and	NULL
Bernabeu	NULL
,	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Camptothecin	NULL
induces	NULL
differentiation	NULL
and	NULL
stimulates	NULL
the	NULL
expression	NULL
of	NULL
differentiation-related	NULL
genes	NULL
in	NULL
U-937	NULL
human	NULL
promonocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

52	NULL
,	NULL
1245-1251	NULL
.	NULL

Ballester	NULL
,	NULL
A.	NULL
,	NULL
Pérez	NULL
,	NULL
C.	NULL
,	NULL
Aller	NULL
,	NULL
P.	NULL
and	NULL
Mata	NULL
,	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Differentiation	NULL
of	NULL
U-937	NULL
promonocytic	NULL
cells	NULL
with	NULL
mitomycin	NULL
C	NULL
or	NULL
cis-diamminedichloroplatinium	NULL
IL	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
65	NULL
,	NULL
791-795	NULL
.	NULL

Beere	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Chresta	NULL
,	NULL
C.	NULL
M.	NULL
and	NULL
Hickman	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Selective	NULL
inhibition	NULL
of	NULL
topoisomerase	NULL
II	NULL
by	NULL
ICRF-193	NULL
does	NULL
not	NULL
support	NULL
a	NULL
role	NULL
for	NULL
topoisomerase	NULL
II	NULL
activity	NULL
in	NULL
the	NULL
fragmentation	NULL
of	NULL
chromatin	NULL
during	NULL
apoptosis	NULL
of	NULL
human	NULL
leukemia	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

49	NULL
,	NULL
842-851	NULL
.	NULL

Bertrand	NULL
,	NULL
R.	NULL
,	NULL
Solary	NULL
,	NULL
E.	NULL
,	NULL
Jenkins	NULL
.	NULL

,	NULL
J.	NULL
and	NULL
Pommier	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Apoptosis	NULL
and	NULL
its	NULL
modulation	NULL
in	NULL
human	NULL
promyelocytic	NULL
cells	NULL
treated	NULL
with	NULL
DNA	NULL
topoisomerase	NULL
I	NULL
and	NULL
II	NULL
inhibitors	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

207	NULL
,	NULL
388-397	NULL
.	NULL

Bessho	NULL
,	NULL
R.	NULL
,	NULL
Matsubara	NULL
,	NULL
K.	NULL
,	NULL
Kubota	NULL
,	NULL
M.	NULL
,	NULL
Kuwakado	NULL
,	NULL
K.	NULL
,	NULL
Hirota	NULL
,	NULL
H.	NULL
,	NULL
Wakazono	NULL
,	NULL
Y.	NULL
,	NULL
Lin	NULL
,	NULL
Y.	NULL
W.	NULL
,	NULL
Okuda	NULL
,	NULL
A.	NULL
,	NULL
Kawai	NULL
,	NULL
M.	NULL
,	NULL
Nishikomori	NULL
,	NULL
R.	NULL
and	NULL
Heike	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Pyrrolidone	NULL
dithiocarbamate	NULL
,	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
nuclear	NULL
factor	NULL
xB	NULL
(	NULL
NF-KB	NULL
)	NULL
activation	NULL
,	NULL
prevents	NULL
apoptosis	NULL
in	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
HL-60	NULL
cells	NULL
and	NULL
thymocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

48	NULL
,	NULL
1883-1889	NULL
.	NULL

Brach	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Hass	NULL
,	NULL
R.	NULL
,	NULL
Sherman	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Guniji	NULL
,	NULL
H.	NULL
,	NULL
Weichselbaum	NULL
,	NULL
R.	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Ionizing	NULL
radiation	NULL
induces	NULL
expression	NULL
and	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
KB	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88	NULL
,	NULL
691-695	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
HL-60	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
:	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
cellular	NULL
oncogene	NULL
expression	NULL
.	NULL

Blood	NULL
70	NULL
,	NULL
1233-1244	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Bodner	NULL
,	NULL
A.	NULL
,	NULL
Ting	NULL
,	NULL
R.	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
morphological	NULL
and	NULL
fuctional	NULL
differentiation	NULL
of	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
(	NULL
HL60	NULL
)	NULL
by	NULL
compounds	NULL
which	NULL
induce	NULL
cell	NULL
differentiation	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
25	NULL
,	NULL
213-218	NULL
.	NULL

Constantinou	NULL
,	NULL
A.	NULL
,	NULL
Henning-Chubb	NULL
,	NULL
C.	NULL
and	NULL
Huberman	NULL
,	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Novobiocin-and	NULL
phorbol-12-myristate-13-acetate-induced	NULL
differentiation	NULL
of	NULL
human	NULL
leukemia	NULL
cells	NULL
associated	NULL
with	NULL
a	NULL
reduction	NULL
of	NULL
topoisomerase	NULL
II	NULL
activity	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

49	NULL
,	NULL
1110-1117	NULL
.	NULL

Constantinou	NULL
,	NULL
A.	NULL
,	NULL
Grdina	NULL
,	NULL
D.	NULL
,	NULL
Kiguchi	NULL
,	NULL
K.	NULL
and	NULL
Huberman	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
topoisomerase	NULL
inhibitors	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
differentiation	NULL
markers	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
K-562	NULL
human	NULL
leukemia	NULL
cells	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

203	NULL
,	NULL
100-105	NULL
.	NULL

Cotter	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
Fernandes	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Verhaegen	NULL
,	NULL
S.	NULL
and	NULL
McCarthey	NULL
,	NULL
J.	NULL
V.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Cell	NULL
death	NULL
in	NULL
the	NULL
myeloid	NULL
lineage	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

142	NULL
,	NULL
93-112	NULL
.	NULL

D'Arpa	NULL
,	NULL
P.	NULL
and	NULL
Liu	NULL
,	NULL
L.	NULL
F.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Topoisomerase-targeting	NULL
antitumor	NULL
drugs	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
989	NULL
,	NULL
163-177	NULL
.	NULL

Dudley	NULL
,	NULL
D.	NULL
,	NULL
Baker	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Hickey	NULL
,	NULL
M.	NULL
J.	NULL
and	NULL
Hickstein	NULL
,	NULL
D.	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
surface	NULL
antigen	NULL
and	NULL
mRNA	NULL
for	NULL
the	NULL
CD11¢	NULL
(	NULL
aX	NULL
,	NULL
p150	NULL
)	NULL
subunit	NULL
of	NULL
the	NULL
human	NULL
leukocyte	NULL
adherence	NULL
receptor	NULL
family	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

160	NULL
,	NULL
346-353	NULL
.	NULL

Durkin	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Chakravarky	NULL
,	NULL
B.	NULL
,	NULL
Tremblay	NULL
,	NULL
R.	NULL
,	NULL
Jouishomme	NULL
,	NULL
H.	NULL
,	NULL
Whitfield	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Biquard	NULL
,	NULL
J.	NULL
M.	NULL
and	NULL
Krsmanovie	NULL
,	NULL
V.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Evidence	NULL
that	NULL
a	NULL
novel	NULL
human	NULL
differentiation-inhibiting	NULL
protein	NULL
blocks	NULL
the	NULL
dimethyl	NULL
sulfoxide-induced	NULL
differentiation	NULL
of	NULL
erythroleukemia	NULL
cells	NULL
by	NULL
inhibiting	NULL
the	NULL
activation	NULL
of	NULL
membrane	NULL
protein	NULL
kinase	NULL
C.	NULL
Cancer	NULL
Res	NULL
.	NULL

52	NULL
,	NULL
6329-6334	NULL
.	NULL

Hallahan	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Sukhatme	NULL
,	NULL
V.	NULL
P.	NULL
,	NULL
Sherman	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Virudachalam	NULL
,	NULL
S.	NULL
,	NULL
Kufe	NULL
,	NULL
D.	NULL
and	NULL
Weichselbaum	NULL
,	NULL
R.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
mediates	NULL
x-ray	NULL
inducibility	NULL
of	NULL
nuclear	NULL
signal	NULL
transducers	NULL
EGR1	NULL
and	NULL
JUN	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
2156-2160	NULL
.	NULL

Hass	NULL
,	NULL
R.	NULL
,	NULL
Brach	NULL
,	NULL
M.	NULL
,	NULL
Gunji	NULL
,	NULL
H.	NULL
,	NULL
Kharbanda	NULL
,	NULL
S.	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
EGR	NULL
and	NULL
NF-KB	NULL
gene	NULL
expression	NULL
by	NULL
dexamethasone	NULL
during	NULL
phorbol	NULL
ester-induced	NULL
human	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Biockem	NULL
.	NULL

Pharmacol	NULL
.	NULL

44	NULL
,	NULL
1569-1576	NULL
.	NULL

Hickstein	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Back	NULL
,	NULL
A.	NULL
L.	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
CD11b	NULL
and	NULL
CD18	NULL
subunits	NULL
of	NULL
the	NULL
neutrophil	NULL
adherence	NULL
receptor	NULL
during	NULL
human	NULL
myeloid	NULL
differentiation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
346-353	NULL
.	NULL

Ishida	NULL
,	NULL
R.	NULL
,	NULL
Miki	NULL
,	NULL
T.	NULL
,	NULL
Narita	NULL
,	NULL
T.	NULL
,	NULL
Yui	NULL
,	NULL
R.	NULL
,	NULL
Sato	NULL
,	NULL
M.	NULL
,	NULL
Utsumi	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Tanabe	NULL
,	NULL
K.	NULL
and	NULL
Andoh	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
intracellular	NULL
topoisomerase	NULL
II	NULL
by	NULL
antitumor	NULL
bis	NULL
(	NULL
2,6-dioxopiperazine	NULL
)	NULL
derivatives	NULL
:	NULL
Mode	NULL
of	NULL
cell	NULL
growth	NULL
inhibition	NULL
distinct	NULL
from	NULL
that	NULL
of	NULL
cleavable	NULL
complex-forming	NULL
type	NULL
inhibitors	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

51	NULL
,	NULL
4909-4916	NULL
.	NULL

Ishida	NULL
,	NULL
R.	NULL
,	NULL
Sato	NULL
,	NULL
M.	NULL
,	NULL
Narita	NULL
,	NULL
T.	NULL
,	NULL
Utsumi	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Nishimoto	NULL
,	NULL
T.	NULL
,	NULL
Morita	NULL
,	NULL
T.	NULL
,	NULL
Nagata	NULL
,	NULL
H.	NULL
and	NULL
Andoh	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
DNA	NULL
topoisomerse	NULL
II	NULL
by	NULL
ICRF-193	NULL
induces	NULL
polyploidization	NULL
by	NULL
uncoupling	NULL
chromosome	NULL
dynamics	NULL
from	NULL
other	NULL
cell	NULL
cycle	NULL
events	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

126	NULL
,	NULL
1341-1351	NULL
.	NULL

Kohn	NULL
,	NULL
K.	NULL
W.	NULL
,	NULL
Ewing	NULL
,	NULL
R.	NULL
A.	NULL
G.	NULL
,	NULL
Erickson	NULL
,	NULL
L.	NULL
C.	NULL
and	NULL
Z	NULL
welling	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
strand	NULL
breaks	NULL
and	NULL
cross-links	NULL
by	NULL
alkaline	NULL
elution	NULL
,	NULL
in	NULL
DNA	NULL
Repair	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
of	NULL
Research	NULL
Procedures	NULL
(	NULL
ed	NULL
.	NULL

R.	NULL
C.	NULL
Friedberg	NULL
and	NULL
P.	NULL
C.	NULL
Hasnawalt	NULL
)	NULL
.	NULL

pp	NULL
.	NULL

379-401	NULL
.	NULL

Marcel	NULL
Dekker	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Kondo	NULL
,	NULL
K.	NULL
,	NULL
Tsuneizumi	NULL
,	NULL
K.	NULL
,	NULL
Watanabe	NULL
,	NULL
T.	NULL
and	NULL
Oishi	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
mouse	NULL
embryonal	NULL
carcinoma	NULL
(	NULL
F	NULL
)	NULL
cells	NULL
by	NULL
inhibitors	NULL
of	NULL
topoisomerases	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

51	NULL
,	NULL
5398-5404	NULL
.	NULL

Kung	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Zetterberg	NULL
,	NULL
A.	NULL
,	NULL
Sherwood	NULL
,	NULL
S.	NULL
W.	NULL
and	NULL
Schimke	NULL
,	NULL
R.	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Differentiation	NULL
by	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
-	NULL
343	NULL
Cytotoxic	NULL
effects	NULL
of	NULL
cell	NULL
cycle	NULL
phase	NULL
specific	NULL
agents	NULL
:	NULL
results	NULL
of	NULL
cell	NULL
cycle	NULL
perturbation	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

50	NULL
,	NULL
7307-7317	NULL
.	NULL

Larcher	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Cordeau-Lossauarn	NULL
,	NULL
L.	NULL
,	NULL
Romey	NULL
,	NULL
G.	NULL
,	NULL
Gros	NULL
,	NULL
E.	NULL
,	NULL
Croizat	NULL
,	NULL
B.	NULL
and	NULL
Vayssiere	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Adriamycin	NULL
promotes	NULL
neurite	NULL
outgrowth	NULL
in	NULL
the	NULL
'neurite-minus	NULL
'	NULL
N1A-103	NULL
mouse	NULL
neuroblastoma	NULL
cell	NULL
line	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

203	NULL
,	NULL
72-79	NULL
.	NULL

Makowske	NULL
,	NULL
M.	NULL
,	NULL
Ballester	NULL
,	NULL
R.	NULL
,	NULL
Cayres	NULL
,	NULL
Y.	NULL
and	NULL
Rosen	NULL
,	NULL
O.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

Immunochemical	NULL
evidence	NULL
that	NULL
three	NULL
protein	NULL
kinase	NULL
C	NULL
isozymes	NULL
increase	NULL
in	NULL
abundance	NULL
during	NULL
HL-60	NULL
differentiation	NULL
induced	NULL
by	NULL
dimethyl	NULL
sulfoxide	NULL
and	NULL
retinoic	NULL
acid	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263	NULL
,	NULL
3402-3410	NULL
.	NULL

Mata	NULL
,	NULL
F.	NULL
,	NULL
Rius	NULL
,	NULL
C.	NULL
,	NULL
Cabafias	NULL
,	NULL
C.	NULL
,	NULL
Bernabeu	NULL
,	NULL
C.	NULL
and	NULL
Aller	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

S-phase	NULL
inhibitors	NULL
induce	NULL
vimentin	NULL
expression	NULL
in	NULL
human	NULL
promonocytic	NULL
cells	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

259	NULL
,	NULL
171-194	NULL
.	NULL

Mezetti	NULL
,	NULL
G.	NULL
,	NULL
Bagnara	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Monti	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Casolo	NULL
,	NULL
L.	NULL
P.	NULL
,	NULL
Bonsi	NULL
,	NULL
L.	NULL
and	NULL
Brunelli	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

Phorbol	NULL
esters	NULL
,	NULL
but	NULL
not	NULL
the	NULL
hormonal	NULL
form	NULL
of	NULL
vitamin	NULL
D	NULL
,	NULL
induce	NULL
changes	NULL
in	NULL
protein	NULL
kinase	NULL
C	NULL
during	NULL
differentiation	NULL
of	NULL
human	NULL
histiocytic	NULL
lymphoma	NULL
cell	NULL
line	NULL
(	NULL
U-937	NULL
)	NULL
.	NULL

Life	NULL
Sci	NULL
.	NULL

40	NULL
,	NULL
2111-2117	NULL
.	NULL

Nakaya	NULL
,	NULL
K.	NULL
,	NULL
Chou	NULL
,	NULL
S.	NULL
,	NULL
Kaneko	NULL
,	NULL
M.	NULL
and	NULL
Nakamura	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Topoisomerase	NULL
inhibitors	NULL
have	NULL
potent	NULL
differentiation-inducing	NULL
activity	NULL
for	NULL
human	NULL
and	NULL
mouse	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

Jpn	NULL
J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

82	NULL
,	NULL
184-191	NULL
.	NULL

Pérez	NULL
,	NULL
C.	NULL
,	NULL
Campayo	NULL
,	NULL
L.	NULL
,	NULL
Navarro	NULL
,	NULL
P.	NULL
,	NULL
Garcia-Bermejo	NULL
,	NULL
L.	NULL
and	NULL
Aller	NULL
,	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
action	NULL
of	NULL
the	NULL
DNA	NULL
intercalating	NULL
agents	NULL
4	NULL
'	NULL
(	NULL
9-acridinylamino	NULL
)	NULL
methanesulfon-m-anisidide	NULL
and	NULL
14-in	NULL
U-937	NULL
human	NULL
promonocytic	NULL
cells	NULL
:	NULL
relationship	NULL
between	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

48	NULL
,	NULL
75-82	NULL
.	NULL

Posada	NULL
,	NULL
J.	NULL
,	NULL
Vici	NULL
,	NULL
P.	NULL
and	NULL
Tritton	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
in	NULL
adriamycin	NULL
action	NULL
and	NULL
resistance	NULL
in	NULL
mouse	NULL
sarcoma	NULL
180	NULL
cells	NULL
Cancer	NULL
Res	NULL
.	NULL

49	NULL
,	NULL
6634-6639	NULL
.	NULL

Rappa	NULL
,	NULL
G.	NULL
,	NULL
Lorico	NULL
,	NULL
A.	NULL
and	NULL
Sartorelli	NULL
A.	NULL
C.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
differentiation	NULL
of	NULL
WEHI-3B	NULL
D+	NULL
monomyelocytic	NULL
leukemia	NULL
cells	NULL
by	NULL
inhibitors	NULL
of	NULL
topoisomerase	NULL
II	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

50	NULL
,	NULL
6723-6730	NULL
.	NULL

Rius	NULL
,	NULL
C.	NULL
,	NULL
Zorrilla	NULL
,	NULL
A.	NULL
,	NULL
Cabafias	NULL
,	NULL
C.	NULL
,	NULL
Mata	NULL
,	NULL
F.	NULL
,	NULL
Bernabeu	NULL
,	NULL
C.	NULL
and	NULL
Aller	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Differentiation	NULL
of	NULL
human	NULL
promonocytic	NULL
leukemia	NULL
U-937	NULL
cells	NULL
with	NULL
DNA	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
:	NULL
Induction	NULL
of	NULL
vimentin	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

39	NULL
,	NULL
442-448	NULL
.	NULL

Rius	NULL
,	NULL
C.	NULL
and	NULL
Aller	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Vimentin	NULL
expression	NULL
as	NULL
a	NULL
late	NULL
event	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
human	NULL
promonocytic	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Sci	NULL
.	NULL

101	NULL
,	NULL
395-401	NULL
.	NULL

Roca	NULL
,	NULL
J.	NULL
,	NULL
Ishida	NULL
,	NULL
R.	NULL
,	NULL
Berger	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Andoh	NULL
,	NULL
T.	NULL
and	NULL
Wang	NULL
.	NULL

,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Antitumor	NULL
bisdioxopiperazines	NULL
inhibit	NULL
yeast	NULL
DNA	NULL
topoisomerase	NULL
II	NULL
by	NULL
trapping	NULL
the	NULL
enzyme	NULL
in	NULL
the	NULL
form	NULL
of	NULL
closed	NULL
protein	NULL
clamp	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
1781-1785	NULL
.	NULL

Rubin	NULL
,	NULL
E.	NULL
,	NULL
Kharbanda	NULL
,	NULL
S.	NULL
,	NULL
Guniji	NULL
,	NULL
H.	NULL
and	NULL
Kufe	NULL
.	NULL

D.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
c-Jun	NULL
protooncogene	NULL
in	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
treated	NULL
with	NULL
etoposide	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

39	NULL
,	NULL
697-701	NULL
.	NULL

Rubin	NULL
,	NULL
E.	NULL
,	NULL
Kharbanda	NULL
,	NULL
S.	NULL
,	NULL
Gunji	NULL
,	NULL
H.	NULL
,	NULL
Weichselbaum	NULL
,	NULL
R.	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

cis-Diamminechloroplatinium	NULL
(	NULL
II	NULL
)	NULL
induces	NULL
c-jur	NULL
expression	NULL
in	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
:	NULL
potential	NULL
involvement	NULL
of	NULL
a	NULL
protein	NULL
kinase	NULL
C-dependent	NULL
signalling	NULL
pathway	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

52	NULL
,	NULL
878-882	NULL
.	NULL

Rubin	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
Philipott	NULL
,	NULL
K.	NULL
L.	NULL
and	NULL
Brooks	NULL
,	NULL
S.	NULL
F.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
cycle	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Current	NULL
Biol	NULL
.	NULL

3	NULL
,	NULL
391-394	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Schreibert	NULL
,	NULL
E.	NULL
,	NULL
Mathias	NULL
,	NULL
P.	NULL
,	NULL
Miiller	NULL
,	NULL
M.	NULL
M.	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
lymphoid	NULL
specific	NULL
octamer	NULL
binding	NULL
protein	NULL
(	NULL
OTF-2B	NULL
)	NULL
by	NULL
proteolytic	NULL
bandshift	NULL
assay	NULL
(	NULL
PCBA	NULL
)	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
4221-4229	NULL
.	NULL

Sundstrom	NULL
,	NULL
C.	NULL
and	NULL
Nilsson	NULL
,	NULL
K.	NULL
(	NULL
1976	NULL
)	NULL
.	NULL

Establishment	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
hystiocytic	NULL
lymphoma	NULL
cell	NULL
line	NULL
(	NULL
U-937	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
17	NULL
,	NULL
565-577	NULL
.	NULL

Tanabe	NULL
,	NULL
K.	NULL
,	NULL
Ikegami	NULL
,	NULL
Y.	NULL
,	NULL
Ishida	NULL
,	NULL
R.	NULL
and	NULL
Andoh	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
topoisomerase	NULL
II	NULL
by	NULL
antitumour	NULL
agent	NULL
Bis	NULL
(	NULL
2	NULL
,	NULL
6-dioxopiperazine	NULL
)	NULL
derivatives	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

51	NULL
,	NULL
4903-4908	NULL
.	NULL

Vosberg	NULL
,	NULL
H.	NULL
P.	NULL
(	NULL
1985	NULL
)	NULL
.	NULL

DNA	NULL
topoisomerases	NULL
:	NULL
enzymes	NULL
that	NULL
control	NULL
DNA	NULL
conformation	NULL
.	NULL

Curr	NULL
:	NULL
Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

114	NULL
,	NULL
19-102	NULL
.	NULL

Wangenheim	NULL
,	NULL
K.	NULL
H.	NULL
and	NULL
Howard	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
.	NULL

Different	NULL
modes	NULL
of	NULL
cell	NULL
sterilization	NULL
:	NULL
cell	NULL
killing	NULL
and	NULL
early	NULL
differentiation	NULL
.	NULL

Radiat	NULL
.	NULL

Res	NULL
.	NULL

73	NULL
,	NULL
288-302	NULL
.	NULL

Yasuda	NULL
,	NULL
L.	NULL
,	NULL
Kishimoto	NULL
,	NULL
A.	NULL
,	NULL
Tanaka	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Tominaga	NULL
,	NULL
M.	NULL
,	NULL
Sakuri	NULL
,	NULL
A.	NULL
and	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

A	NULL
synthetic	NULL
peptide	NULL
substrate	NULL
for	NULL
selective	NULL
assay	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

166	NULL
,	NULL
1220-1227	NULL
.	NULL

(	NULL
Received	NULL
3	NULL
July	NULL
1996	NULL
-	NULL
Accepted	NULL
29	NULL
November	NULL
1996	NULL
)	NULL

